views
Europe’s drugs regulator said on Friday its safety panel found no evidence that Gilead’s remdesivir caused kidney problems in some COVID-19 patients.
Remdesivir, sold under the brand name Veklury, was conditionally approved in Europe in July for treating COVID-19 in adults and adolescents with pneumonia requiring oxygen support.
The European Medicines Agency (EMA) said to arrive at the conclusion the panel (PRAC) had assessed data provided by the U.S.-based drugmaker, analyses of reported adverse reactions, data from trials and published work on COVID-19 patients with acute kidney injury. https://bit.ly/2Z8PDyK
Separately, the PRAC also said it was not yet clear if there was any connection between remdesivir and reports of sinus bradycardia – or slow heartbeat – in COVID-19 patients, and started a new assessment for the same.
PRAC started an in-depth evaluation of all available data after Italy’s regulator raised concerns about 11 cases of sinus bradycardia in patients who had received remdesivir, the EMA said.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Read all the Latest News, Breaking News and Coronavirus News here
Comments
0 comment